News
Unconvinced by NHS test run, NICE rejects BMS' Opdivo in hea...
NICE has rejected Bristol Myers Squibb’s immunotherapy Opdivo as a second-line treatment for head and neck cancer in first draft guidance, unconvinced by evidence unearthed during a three-y
